GAPDH

Across TCGA pan-cancer cohorts, GAPDH Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GAPDH data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GAPDH Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GAPDH expression acts as an unfavorable survival marker.

HNSC, BLCA, and LUAD are the cancer types where GAPDH Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.501	0.751	<.001	46	view →
BLCA	OS	Median	All	0.195	0.720	.009	18	view →
LUAD	DFS	Median	All	0.098	0.791	<.001	18	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →
SARC	DFS	Median	All	0.109	0.611	.030	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GAPDH–HNSC (OS)

Open the HNSC breakdown →